Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Cell · 2023-10 · 186 (22) · 4757-4772
DOI: 10.1016/j.cell.2023.09.023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell, 2023-10. Verfasst von Adam L Boxer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Memory and Aging Center, Department of Neurology, Weill Institute of Neuroscience, University of California, San Francisco, San Francisco, CA, USA. E…. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Development. Die Arbeit wurde bisher 211-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memory and Aging Center, Department of Neurology, Weill Institute of Neuroscience, University of California, San Francisco, San Francisco, CA, USA. Electronic address: adam.boxer@ucsf.edu.
- Center for Alzheimer Research and Treatment, Department of Neurology, MassGeneral Brigham, Harvard Medical School, Boston, MA, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Boxer, A. L., & Sperling, R. (2023). Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials. Cell, 186(22), 4757-4772. https://doi.org/10.1016/j.cell.2023.09.023
Vancouver
Boxer AL, Sperling R. Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials. Cell. 2023;186(22):4757-4772. doi:10.1016/j.cell.2023.09.023
BibTeX
@article{Boxer2023,
author = {Boxer, Adam L and Sperling, Reisa},
title = {Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials},
journal = {Cell},
year = {2023},
volume = {186},
number = {22},
pages = {4757--4772},
doi = {10.1016/j.cell.2023.09.023}
}
EUVIMED